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SUMMARY – Multiple sclerosis is a chronic, immune-mediated disease of the central nervous 
system that typically strikes young adults. It is often associated with a wide range of functional 
deficits and progressive disability. Common symptoms of multiple sclerosis include vision problems, 
spasticity, weakness, ataxia, bladder and bowel dysfunctions, fatigue, pain syndromes, tremors, ver-
tigo, cognitive impairment, and mood disorders. Multiple sclerosis has a major negative impact on 
patient health-related quality of life (HRQoL). Quality of life (QoL) is a multidimensional con-
struct composed of functional, physical, emotional, social and spiritual well-being. Researches have 
reported that individuals with multiple sclerosis have lower QoL than non-diseased and diseased 
populations. The inclusion of HRQoL questionnaires in the patient follow-up is a relevant issue to 
optimize treatment, facilitate treatment decisions and improve adherence, as well as to reduce the 
inconveniences derived from medication such as side effects.
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Multiple sclerosis (MS) is a chronic, inflamma-
tory, immune-mediated disease of the central nervous 
system that usually strikes young adults, with a higher 
incidence in women. The mean annual MS incidence 
rate in Europe is 4.3 cases per 100 0001,2. This chronic 
demyelinating disease involves unpredictable episodes 
of inflammatory demyelination and axonal transec-
tion that result in lesions along axons of nerve fibers 
in the brain and spinal cord3‚4. The symptoms of MS, 
such as weakness, sensory loss, and ataxia, which are 
directly related to demyelination and axonal loss, 
along with other symptoms such as reactive depres-
sion or social isolation, can result in functional limi-
tations, disability and reduced quality of life (QoL)5. 
Studies have reported that individuals with MS have 
lower overall and specific QoL than non-diseased 
controls and populations with other chronic diseases 
like diabetes, epilepsy, rheumatoid arthritis, and oth-
ers6,7. The treatment of MS is divided into treatment 
of MS relapses, prevention of new relapses and disease 
progression, and symptomatic treatment8. Symptom 
management includes medications, surgical proce-
dures and nonpharmacological methods such as reha-
bilitation and psychosocial support9,10. Lots of journal 
articles describe the importance of different rehabili-
tation interventions that can be used throughout the 
course of the disease, from the initial symptoms to the 
advanced stages of MS11. Many patients with MS ex-
plore complementary and alternative medicine (CAM) 
treatments to help control their disease and treat MS 
symptoms12. Physicians and nurses usually direct the 
pharmacological management, while an integrated 
team of many healthcare professionals collaborate to 
minimize the functional impact and the effects of the 
disease on disability, handicaps, and QoL11. Since MS 
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may result in a vast number of neurological problems, 
an interdisciplinary healthcare team is essential for 
maximizing the patient’s ability to function. An inte-
grated team may have many members, including phy-
sicians, nurses, physical therapists, psychotherapists, 
occupational therapists, speech and language patholo-
gists, social workers, vocational rehabilitation thera-
pists, patients, families, and other caregivers11,12. The 
inclusion of health-related quality of life (HRQoL) 
questionnaires in the patient follow-up is a relevant 
issue to optimize treatment, facilitate treatment deci-
sions and improve adherence, as well as to reduce the 
inconveniences derived from medication such as side 
effects13.
Health-related quality of life is a multidimensional 
concept that includes self-reported measures of physi-
cal, mental, emotional and social functioning. These 
measures have become very important as clinical trial 
outcome measures in MS14,15. Multiple sclerosis has a 
major negative impact on patient HRQoL16. The first 
study of HRQoL in MS was published in 1990 and the 
first comparative study appeared two years later17,18. In 
chronic debilitating diseases such as MS, long-term 
preservation of HRQoL should be regarded as a criti-
cal marker of therapeutic success. HRQoL is distilla-
tion of almost every aspect of the patient’s existence, 
including perception of treatment benefit and func-
tional decrements of disease progression19,20. Clearly, 
then, the utility of HRQoL measurement tools de-
pends on their ability to accurately and consistently 
quantify QoL during the course of the disease21.
QoL scales for patients with MS could be divided 
into universal or general and specific for the disease 
or disease-oriented20,22. The scales used to assess 
QoL in MS include either subjective or objective in-
dicators, or both21. Subjective factors in QoL in MS 
patients include perception of symptoms, level of fit-
ness, self-image, satisfaction with family life, work, 
economic situation, interaction with other people, 
social support, and life in general20-22. To the objec-
tive factors, we should include clinical picture of the 
disease, social status, social and living conditions, 
and the number and intensity of social contacts22. 
The questionnaire may be completed by the patient 
in person or by telephone interview, by family mem-
bers or close persons, by professional caregivers and 
health professionals22,23. The most desirable and reli-
able is assessment by the patient himself, especially 
when the subjects of measurement are subjective 
aspects of QoL. Among the generic questionnaires 
used in other disease entities, the assessment of QoL 
in patients with MS mostly used are Medical Out-
come Study 36-Item Short Form Health Survey (SF-
36), EuroQol EQ-5D, Sickness Impact Profile (SIP), 
Life Satisfaction Questionnaire (LSQ ), WHOQOL 
BREF and Quality of Well-Being Scale (QWBS)24-
29. The above-mentioned questionnaires have been 
tested in many countries. In the literature, there are 
numerous and detailed data on their validity and re-
liability, also in relation to MS21,22. One of the most 
commonly used scales specific to MS is the Multiple 
Sclerosis Quality of Life Instrument (MSQoL-54) 
by Barbara Vickrey and colleagues from the Univer-
sity of California in Los Angeles22,30. This scale is 
a modification of the SF-36, to which 18 questions 
specific to MS have been added22. Another frequent-
ly used tool is the Functional Assessment of Mul-
tiple Sclerosis (FAMS), published in 1996 by David 
Cella and colleagues, from Chicago. Scoring QoL in 
patients with MS, especially when it is done for sci-
entific purposes, requires measurement of the func-
tional status and fatigue because in addition to de-
pression and cognitive impairment they are the most 
important determinants of QoL in patients with 
MS22,31. Fatigue is one of the most common symp-
toms of MS and it is associated with a reduced QoL5. 
It has recently been reported in the literature that 
fatigue in MS has an increasing frequency22. This 
can be defined as uncontrollable apathy, lack of en-
ergy or feeling exhausted with no link to depression, 
or muscle weakness. In two-thirds of patients with 
MS, it appears as one of the three main symptoms 
and in patient opinion one of the most troublesome 
symptoms of the disease32. The fatigue syndrome in 
patients with MS cannot be evaluated objectively. 
That is why for the evaluation of fatigue more than 
30 scales have been developed. The most frequently 
used are the Fatigue Severity Scale (FSS) by Krupp 
et al. and the Modified Fatigue Impact Scale (Modi-
fied Fatigue Impact Scale, MFIS)33. Depression is 
also commonly associated with MS and occurs in 
as many as 50% of patients34. For the evaluation of 
depression in MS, the most frequently applied meth-
ods are Beck’s Inventory, Hamilton scale, Hospital 
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Anxiety and Depression Scale (HADS), Zung scale 
and Montgomery-Asberg scale (Montgomery-As-
berg Depression Rating Scale, MADRS)9,35-38.
Recognition of MS-fatigue (MSF) and MS-de-
pression (MSD) and understanding their relationship 
to QoL is important because both pharmacological 
and nonpharmacological treatments can be efficacious 
in treating MSF and MSD. Treatment of MSF and 
MSD could potentially help improve QoL of MS pa-
tients, regardless of neurological disability16.
Conclusion
Chronic diseases like MS present unique challeng-
es and opportunities for patients and the medical care 
system. Patients are challenged because they are un-
der tremendous pressure to actively engage themselves 
in prevention, treatment, and health maintenance be-
haviors, often before they feel ready to do so. Health 
care providers are challenged because health-promo-
tion activities require more time, counseling skills, 
and organizational resources than traditional, acute 
medical care39. The incomplete recovery after relapses, 
the accumulation of new deficits, and the progressive 
nature of the condition interfere with daily activities 
of individuals and have negative impact on their well-
being. Indeed, studies show that QoL measurements 
are constantly lower in patients with MS. Estimation 
of HRQoL is being increasingly recognized as nec-
essary when analyzing the effectiveness of treatment 
modalities and in follow up of patients with chronic 
diseases such as MS40. Previously performed clinical 
trials identified the main factors related to  HRQoL: 
physical factors (sensitive/motor deficits, fatigue, 
pain, and sexual/bladder dysfunction), psychological 
factors (depression, anxiety, cognitive disturbances, 
and coping strategies) and social factors (family/social 
relationships and work activity). HRQoL indicators 
require completion of a well-validated questionnaire. 
The inclusion of HRQoL questionnaires in the patient 
follow up is a relevant issue to optimize treatment, fa-
cilitating treatment decisions and improving adher-
ence, as well as to reduce the inconveniences derived 
from medication such as side effects6. HRQoL mea-
surements have become an important outcome both 
for population health assessment and for evaluating 
treatments and care management41.
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Sažetak
KVALITETA ŽIVOTA U BOLESNIKA S MULTIPLOM SKLEROZOM
V. Bašić Kes, Lj. Čengić, M. Cesarik, A. Jadrijević Tomas, I. Zavoreo, L. Zadro Matovina, L. Ćorić, S. Drnasin i V. Demarin
Multipla skleroza je kronična, imuno posredovana bolest središnjega živčanog sustava, koja obično pogađa odrasle lju-
de mlađe životne dobi. Često je povezana sa širokim rasponom funkcionalnog deficita i progresivne nesposobnosti. Uobi-
čajeni simptomi multiple skleroze su smetnje vida, spastičnost, slabost, ataksija, smetnje kontrole mokrenja i stolice, umor, 
bolni sindromi, tremor, vrtoglavica, pogoršanje kognitivnih funkcija i poremećaji raspoloženja. Multipla skleroza ima 
značajan negativan utjecaj na kvalitetu života oboljelih od ove bolesti. Kvaliteta života je multidimenzionalna formulacija 
sastavljena od funkcionalnih, fizičkih, emocionalnih, socijalnih i duhovnih čimbenika zdravlja. Istraživanja su pokazala da 
oboljeli od multiple skleroze imaju nižu kvalitetu života od zdrave populacije i oboljelih od nekih drugih kroničnih bolesti. 
Uključivanje upitnika o kvaliteti života u praćenju bolesnika je važno u optimiziranju liječenja, određivanju i odlučivanju 
o vrsti liječenja i poboljšanju suradljivosti, kao i u smanjenju neugodnosti koje proizlaze iz liječenja, kao što je primjerice 
pojava nuspojava primijenjenih lijekova.
Ključne riječi: Multipla skleroza – kvaliteta života; Multipla skleroza – terapija

